Health Care Center, Kitasato University, Kanagawa, Japan.
Diabetes Care. 2013 Sep;36(9):2803-9. doi: 10.2337/dc12-2327. Epub 2013 Apr 25.
To examine the interactive relationship between diabetic retinopathy (DR) and diabetic nephropathy (DN) in type 2 diabetic patients and to elucidate the role of DR and microalbuminuria on the onset of macroalbuminuria and renal function decline.
We explored the effects of DR and microalbuminuria on the progression of DN from normoalbuminuria and low microalbuminuria (<150 mg/gCr) to macroalbuminuria or renal function decline in the Japan Diabetes Complications Study (JDCS), which is a nationwide randomized controlled study of type 2 diabetic patients focusing on lifestyle modification. Patients were divided into four groups according to presence or absence of DR and MA: normoalbuminuria without DR [NA(DR-)] (n = 773), normoalbuminuria with DR [NA(DR+)] (n = 279), microalbuminuria without DR [MA(DR-)] (n = 277), and microalbuminuria with DR [MA(DR+)] (n = 146). Basal urinary albumin-to-creatinine ratio and DR status were determined at baseline and followed for a median of 8.0 years.
Annual incidence rates of macroalbuminuria were 1.6/1,000 person-years (9 incidences), 3.9/1,000 person-years (8 incidences), 18.4/1,000 person-years (34 incidences), and 22.1/1,000 person-years (22 incidences) in the four groups, respectively. Multivariate-adjusted hazard ratios of the progression to macroalbuminuria were 2.48 (95% CI 0.94-6.50; P = 0.07), 10.40 (4.91-22.03; P < 0.01), and 11.55 (5.24-25.45; P < 0.01) in NA(DR+), MA(DR-), and MA(DR+), respectively, in comparison with NA(DR-). Decline in estimated glomerular filtration rate (GFR) per year was two to three times faster in MA(DR+) (-1.92 mL/min/1.73 m(2)/year) than in the other groups.
In normo- and low microalbuminuric Japanese type 2 diabetic patients, presence of microalbuminuria at baseline was associated with higher risk of macroalbuminuria in 8 years. Patients with microalbuminuria and DR showed the fastest GFR decline. Albuminuria and DR should be considered as risk factors of renal prognosis in type 2 diabetic patients. An open sharing of information will benefit both ophthalmologists and diabetologists.
研究 2 型糖尿病患者中糖尿病视网膜病变(DR)与糖尿病肾病(DN)之间的相互关系,并阐明 DR 和微量白蛋白尿在大白蛋白尿和肾功能下降发生中的作用。
我们在日本糖尿病并发症研究(JDCS)中探讨了 DR 和微量白蛋白尿对从正常白蛋白尿和低微量白蛋白尿(<150mg/gCr)进展为大白蛋白尿或肾功能下降的 DN 的影响,该研究是一项针对 2 型糖尿病患者的全国性随机对照生活方式改变研究。患者根据是否存在 DR 和 MA 分为四组:无 DR 的正常白蛋白尿[NA(DR-)](n=773),有 DR 的正常白蛋白尿[NA(DR+)](n=279),无 DR 的微量白蛋白尿[MA(DR-)](n=277)和有 DR 的微量白蛋白尿[MA(DR+)](n=146)。在基线时确定基础尿白蛋白与肌酐比值和 DR 状态,并随访中位数为 8.0 年。
四组的大白蛋白尿年发生率分别为 1.6/1000 人年(9 例),3.9/1000 人年(8 例),18.4/1000 人年(34 例)和 22.1/1000 人年(22 例)。与 NA(DR-)相比,NA(DR+)、MA(DR-)和 MA(DR+)的大白蛋白尿进展的多变量调整后的危险比分别为 2.48(95%CI 0.94-6.50;P=0.07)、10.40(4.91-22.03;P<0.01)和 11.55(5.24-25.45;P<0.01)。MA(DR+)的估算肾小球滤过率(GFR)每年下降速度比其他组快两到三倍(-1.92ml/min/1.73m2/year)。
在日本 2 型糖尿病的正常和低微量白蛋白尿患者中,基线时存在微量白蛋白尿与 8 年内发生大白蛋白尿的风险较高相关。伴有微量白蛋白尿和 DR 的患者显示出最快的 GFR 下降。白蛋白尿和 DR 应被视为 2 型糖尿病患者肾脏预后的危险因素。眼科医生和糖尿病医生之间的信息公开共享将使双方受益。